Inhibition of CYP2D6 activity by bupropion

Journal of Clinical Psychopharmacology

Volumn 25, Issue 3, 2005, Pages 226-229

  Kotlyar, Michael ^a,b   Brauer, Lisa H ^b   Tracy, Timothy S ^a   Hatsukami, Dorothy K ^b   Harris, Jennifer ^b   Bronars, Carrie A ^b   Adson, David E ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; CYTOCHROME P450 2D6; DEXTROMETHORPHAN; DEXTRORPHAN; GUAIFENESIN; PLACEBO;

ADULT; ARTICLE; CIGARETTE SMOKING; CONTROLLED STUDY; DRUG EFFECT; DRUG METABOLISM; DRUG URINE LEVEL; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; MALE; PHENOTYPE; PRIORITY JOURNAL; SMOKING CESSATION; SUSTAINED DRUG RELEASE;

ADULT; BUPROPION; CYTOCHROME P-450 CYP2D6; DEXTROMETHORPHAN; DRUG INTERACTIONS; ENZYME INHIBITORS; FEMALE; HUMANS; MALE; MIDDLE AGED;

EID: 18844458608     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000162805.46453.e3     Document Type: Article

References (27)

1. Greenblatt DJ, von Moltke LL, Harmatz JS, et al. Human cytochromes and some newer antidepressants: kinetics, metabolism, and drug interactions. J Clin Psychopharmacol. 1999;19:23S-35S.
2. Katon WJ. Clinical and health services relationships between major depression, depressive symptoms, and general medical illness. Biol Psychiatry. 2003;54:216-226.
3. Product information. Zyban (bupropion hydrochloride) sustained release tablets. Research Triangle Park, NC: GlaxoSmithKline; 2004.
4. Faucette SR, Hawke RL, Lecluyse EL, et al. Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. Drug Metab Dispos. 2000;28:1222-1230.
5. Hesse LM, Venkatakrishnan K, Court MH, et al. CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab Dispos. 2000;28:1176-1183.
6. Pollock BG, Sweet RA, Kirshner M, et al. Bupropion plasma levels and CYP2D6 phenotype. Ther Drug Monit. 1996;18:581-585.
7. Shad MU, Preskorn SH. A possible bupropion and imipramine interaction. J Clin Psychopharmacol. 1997;17:118-119.
8. Guzey C, Norstrom A, Spigset O. Change from the CYP2D6 extensive metabolizer to the poor metabolizer phenotype during treatment with bupropion. Ther Drug Monit. 2002;24:436-437.
9. Weintraub D. Nortriptyline toxicity secondary to interaction with bupropion sustained-release. Depress Anxiety. 2001;13:50-52.
10. McCollum DL, Greene JL, McGuire DK. Severe sinus bradycardia after initiation of bupropion therapy: a probable drug-drug interaction with metoprolol. Cardiovasc Drugs Ther. 2004;18:329-330.
11. Schmid B, Bircher J, Preisig R, et al. Polymorphic dextromethorphan metabolism: co-segregation of oxidative O-demethylation with debrisoquine hydroxylation. Clin Pharmacol Ther. 1985;38:618-624.
12. Spitzer RL, Williams JB, Kroenke K, et al. Utility of a new procedure for diagnosing mental disorders in primary care. The PRIME-MD 1000 study. JAMA. 1994;272:1749-1756.
13. Ducharme J, Abdullah S, Wainer IW. Dextromethorphan as an in vivo probe for the simultaneous determination of CYP2D6 and CYP3A activity. J Chromatogr B Biomed Appl. 1996;678:113-128.
14. Straka RJ, Hansen SR, Walker PF. Comparison of the prevalence of the poor metabolizer phenotype for CYP2D6 between 203 Hmong subjects and 280 white subjects residing in Minnesota. Clin Pharmacol Ther. 1995;58:29-34.
15. Hamelin BA, Bouayad A, Methot J, et al. Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity. Clin Pharmacol Ther. 2000;67:466-477.
16. Palovaara S, Pelkonen O, Uusitalo J, et al. Inhibition of cytochrome P450 2B6 activity by hormone replacement therapy and oral contraceptive as measured by bupropion hydroxylation. Clin Pharmacol Ther. 2003;74:326-333.
17. Alfaro CL, Lam YW, Simpson J, et al. CYP2D6 status of extensive metabolizers after multiple-dose fluoxetine, fluvoxamine, paroxetine, or sertraline. J Clin Psychopharmacol. 1999;19:155-163.
18. Alfaro CL, Lam YW, Simpson J, et al. CYP2D6 inhibition by fluoxetine, paroxetine, sertraline, and venlafaxine in a crossover study: intraindividual variability and plasma concentration correlations. J Clin Pharmacol. 2000;40:58-66.
19. Kennedy SH, McCann SM, Masellis M, et al. Combining bupropion SR with venlafaxine, paroxetine, or fluoxetine: a preliminary report on pharmacokinetic, therapeutic, and sexual dysfunction effects. J Clin Psychiatry. 2002;63:181-186.
20. Lessard E, Yessine MA, Hamelin BA, et al. Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans. Pharmacogenetics. 1999;9:435-443.
21. Bloomer JC, Woods FR, Haddock RE, et al. The role of cytochrome P4502D6 in the metabolism of paroxetine by human liver microsomes. Br J Clin Pharmacol. 1992;33:521-523.
22. Hsyu PH, Singh A, Giargiari TD, et al. Pharmacokinetics of bupropion and its metabolites in cigarette smokers versus nonsmokers. J Clin Pharmacol. 1997;37:737-743.
23. Stewart JJ, Berkel HJ, Parish RC, et al. Single-dose pharmacokinetics of bupropion in adolescents: effects of smoking status and gender. J Clin Pharmacol. 2001;41:770-778.
24. Bock KW, Schrenk D, Forster A, et al. The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes. Pharmacogenetics. 1994;4:209-218.
25. Golden RN, De Vane CL, Laizure SC, et al. Bupropion in depression. II. The role of metabolites in clinical outcome. Arch Gen Psychiatry. 1988;45:145-149.
26. Bertelsen KM, Venkatakrishnan K, Von Moltke LL, et al. Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine. Drug Metab Dispos. 2003;31:289-293.
27. Yao C, Kunze KL, Trager WF, et al. Comparison of in vitro and in vivo inhibition potencies of fluvoxamine toward CYP2C19. Drug Metab Dispos. 2003;31:565-571.